They believe that they may be able to do so by altering the environment in which the tumor exists, known as the tumor microenvironment (TME), and the present therapies that target those stromal cells in conjunction with PD-1/PD-L1 could increase the survival of the patient (Mariathasan et al., 2018). Here, PDCD1 is linked to neoplasm.